World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Case Report

Volume 14, Number 1, February 2023, pages 101-107

Long-Term Responders to Erlotinib for Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor: Two Case Reports and a Single-Institutional Retrospective Study

Figures

Figure 1.
Figure 1. Patients’ selection.
Figure 2.
Figure 2. Kaplan-Meier curves of progression-free survival (a) and overall survival (b) of all patients (N = 39).
Figure 3.
Figure 3. Kaplan-Meier curves of progression-free survival (a) and overall survival (b) based on monotherapy (N = 20) and combination (N = 19).
Figure 4.
Figure 4. Histology of bronchoscopical specimen of case 1 (H&E stain). H&E: hematoxylin and eosin.
Figure 5.
Figure 5. Brain metastasis of case 1. (a) Postoperative recurrence in November 2010. (b) Before (in October 2011) and (c) 1 year after (in October 2012) the initiation of pemetrexed and erlotinib. Yellow arrows show the brain metastases.
Figure 6.
Figure 6. Histology of bronchoscopical specimen of case 2 (H&E stain). H&E: hematoxylin and eosin.
Figure 7.
Figure 7. Brain metastases of case 2. Before (in March 2011) (a, b) and 3 months after (in June 2011) (c, d) the initiation of erlotinib monotherapy. (e) Appearance of the left temporal metastasis 3 months after the discontinuation of erlotinib. Yellow arrows show the brain metastases.

Table

Table 1. Patient’s Characteristics and Treatment (N = 39)
 
Bev: bevacizumab; CPT-11: irinotecan; CR: complete response; ECOG-PS: Eastern Cooperative Oncology Group performance status; NE: not evaluated; PEM: pemetrexed; PD: progressive disease; PR: partial response; SD: stable disease.
Backgrounds
  SexMale/female25/14
  AgeMedian (range)65 (42 - 80)
  Smoking statusNon/former/current smokers8/13/18
  ECOG-PS0-1/2/326/12/1
  Distant metastasesBrain/lung/liver/bone/none11/19/5/7/5
Treatment
  LineFirst/second/third/fourth1/30/7/1
  RegimenMonotherapy20
Combination19
Partner drug: PEM/CPT-11/Bev17/1/1
  ResponseCR/PR/SD/PD/NE2/5/10/21/1
OutcomesAlive/dead/unknown2/36/1